Cancer care has historically been responsive treatment, beginning only after a clinical diagnosis. Standard protocols rely on identifying the tumour's origin, analysing symptoms, and staging the disease. Unfortunately, late-stage detections frequently limit treatment efficacy and compromise patient outcomes.
Recent breakthroughs in genomic science are shifting this timeline from reactive treatment to proactive prevention. Today, advanced genetic screenings can identify individuals harbouring cancer-driving mutations long before symptoms manifest. This early insight allows clinicians to implement precise lifestyle interventions and surveillance strategies to actively mitigate cancer risks.
The Role of Precision Oncology Databases
A tumour's behaviour is dictated by specific abnormalities within the roughly 20,000 genes of the human genome. Because these genetic combinations vary uniquely by individual, clinical precision requires extensive data.
Building a robust genetic database involves tracking real-world clinical outcomes alongside specific genetic mutations over many years. This data framework helps oncologists map family medical histories, trace inherited risks across generations, and monitor longitudinal treatment efficacy.
By cross-referencing a patient's unique genetic profile with historical data, clinicians can predict which therapeutic combinations—such as targeted therapies, immunotherapies, or traditional chemotherapies—will be most effective. This tailored approach forms the foundation of precision medicine, transforming how we predict, prevent, and treat oncological diseases.
The Power of Localised Data: Highlighting High-Risk Mutations
For individuals weighing the utility of genetic testing, statistical concentration provides a compelling argument. In hereditary breast and ovarian cancers, mutations within and beyond the BRCA1 and BRCA2 genes, alongside Lynch syndrome (primarily linked to colorectal and endometrial malignancies), account for nearly 90% of all hereditary cases evaluated at the hospital. This concentration underscores a critical truth: family health patterns involving breast, ovarian, or colorectal cancers are the most likely to trace back to a single, identifiable genetic driver.
The most striking insights from our longitudinal database emerge from colorectal cancer screening. Over a four-and-a-half-year period, institutional data revealed that out of 142 colorectal cancer patients evaluated for inherited (germline) mutations, approximately 16% tested positive. This significantly outpaces the global average of 5% to 10%.
This elevated prevalence has led oncologists to prioritise broader genetic screening for colorectal cancer, particularly for individuals diagnosed at a young age or those with a pronounced family history of the disease.
Overcoming Roadblocks to Proactive Care
While the clinical utility of genomic testing is undeniable, systemic challenges remain. Specialised genetic counsellors are currently scarce outside major metropolitan hubs, and the financial cost of testing remains a consideration for many families. However, as sequencing technologies become more deeply integrated into standard medical care, economies of scale are expected to drive down costs.
These temporary hurdles are not a reason to delay. A genetic registry grows exponentially more powerful with scale; each entry sharpens our understanding of which specific mutations manifest within the Indian population and at what frequency.
Capturing Cancer in Practice
For families navigating a high-risk diagnosis, the clinical implications of genetic testing are immediate and profound:
Psychological Relief: A mother can be definitively cleared of unmerited guilt regarding inherited diseases.
Proactive Interventions: A high-risk son can be placed on a personalised colonoscopy schedule a decade earlier than standard guidelines dictate.
Empowered Preemption: A daughter can map her individual risk landscape with her physician long before any anomaly materialises on a radiological scan.
This is what intercepting cancer before its inception looks like in practice. Case by case, one sequence at a time, genetic testing equips us to stay ahead of the disease and redefine the parameters of oncology.